DEINOVE, ESPCI Paris and INRAE awarded grant following the call for proposals of the French “Antibiotic resistance” Prior...
29 Aprile 2021 - 6:00PM
DEINOVE, ESPCI Paris and INRAE awarded grant
following the call for proposals of the French“Antibiotic
resistance” Priority Research Program
- The
Microflu4AMR project, based on microfluidic technology and the
exploitation of soil microbial diversity, will enable the search
and selection of active molecules to meet the challenges of
antibiotic resistance
- The
French ANR will fund the project's academic partners with a €2M
grant
DEINOVE (Euronext Growth Paris: ALDEI), a French
biotech company pioneering the exploration and exploitation of
bacterial biodiversity to address the urgent and global challenge
of antimicrobial resistance, announces that it has been selected
with ESPCI Paris1 and INRAE2 for a project financed by the French
National Agency for Research (ANR) through a 2 million-euros grant,
following an extremely competitive selection process.
The Microflu4AMR project is one of the 11
winners selected - out of over 130 applications - within the
national priority research program (PRP) on antibiotic resistance
by an international jury chaired by Professors Herman Goossens,
Benedikt Huttner, Rafael Canton and comprising 25 world-class
experts3.
Microflu4AMR is complementary to DEINOVE’s
Deinodrop and Boost-ID projects, the latter of which was recently
selected as part of the France Relance call for proposals (where
10% of industrial projects were selected)4.
Boost-ID and Microflu4AMR were submitted under
separate calls for proposals, with independent, demanding, and
highly selective evaluation processes. The evaluations reached the
same conclusion: the microfluidic technology developed by DEINOVE
is considered by the scientific and industrial community as a major
asset for the screening and identification of new therapeutic
solutions from bacterial biodiversity.
Antibiotic resistance has become a major public
health emergency that is now mobilizing the entire international
community5, and of course France. Discovery of new antibiotics is
therefore crucial to address this urgent challenge.
In this regard, the Microflu4AMR project will
actually:
-
Increase knowledge on soil microbial communities allowing the
analysis and selection of soil samples based on their potential for
the discovery of new active antibiotic molecules,
-
Develop and implement a high-throughput system at the single-cell
level for the sorting of antibiotic-producing bacteria from the
aforementioned pre-selected soil samples.
“We are delighted to have been selected as part
of the highly demanding Antibiotic resistance program and to
be able to pursue our technological developments in microfluidics
with the prestigious teams at ESPCI Paris and INRAE”,
said Alexis Rideau, CEO
of DEINOVE. “Combined with DEINOVE’s
cutting-edge expertise in synthetic biology, microfluidics open up
tremendous opportunities for screening at an unprecedented rate
(with a throughput of up to one million bacteria tested per hour),
whilst drastically reducing costs (reagents) and environmental
impact (plastics)”.
ABOUT DEINOVE
DEINOVE is a French biotechnology company
pioneering the exploration of a new domain of life, unexplored at
99.9%: the “microbial dark matter”. By revealing the metabolic
potential of rare bacteria or still classified as uncultivable, it
tackles a global health and economic challenge: antimicrobial
resistance. The new therapies discovered and developed by DEINOVE
target superbugs (microbes that have become resistant to one or
more antimicrobials) that cause life-threatening infections which
are now spreading at high speed.
This breakthrough approach gave rise to one of
the world’s first specialized micro-biotechnology platforms and a
unique collection of nearly 10,000 rare strains and thousands of
bacterial extracts. Today, DEINOVE is conducting several
development programs, of which its first antibiotic candidate is
currently evaluated in a Phase II clinical trial in severe
Clostridioides difficile infections, one of the world’s first
emergencies. The Company has also developed new bacterial
micro-factories that address the other issue in the race against
antimicrobial resistance: the industrial production of these rare
and low concentrated compounds with often too complex chemical
structures to be generated by chemical synthesis.Located at the
heart of the Euromedecine park in Montpellier, DEINOVE has been
listed on EURONEXT GROWTH® (ALDEI – code ISIN FR0010879056) since
2010. The Company has over 50 employees and relies on a network of
world-class academic, technological, industrial and institutional
partners.
ABOUT THE ANTIOBIOTICS RESISTANCE CALL FOR
PROJECTS: “UNDERSTAND, INNOVATE, ACT”
Launched in January 2020 for a 10-year6 period,
the priority research program (PRP) on antibiotic resistance has
the following objectives: to set up an ambitious research program
bringing together all French forces, to propose new public health
strategies and control measures aiming to reduce and optimize the
use of antibiotics in human and veterinary medicine and ultimately
reverse the resistance curve, in line with international
policies.
The Antibiotic resistance “understand, innovate,
act” call for proposals7 launched under the guidance of ANR is the
operational component of this PRP. It aims to support “very
ambitious, structuring, long-term (3 to 6 years) research projects
favoring interdisciplinarity and contributing to the emergence of
synergies between different types of research (fundamental,
environmental, clinical, translational), with the goal of
stimulating and supporting the emergence of diagnostic, preventive
and therapeutic innovations, and ultimately leading to a better use
of antibiotics”.
CONTACTS
InvestorsMario AlcarazChief Financial and Administrative Officer
+33 (0)4 48 19 01 00ir@deinove.comMediaATCG Partners – Marie
PUVIEUX+33 (0)9 81 87 46 72 / +33 (0)6 10 54 36
72communication@deinove.com |
|
1 Advanced School of Industrial Physics and
Chemistry in Paris2 National Research Institute for agriculture,
food and nutrition, and the environment3
https://anr.fr/fileadmin/aap/2020/selection/ia-aap-ppr-amr-2020-jury.pdf
4 See press release March 10, 20215 Carlet Report
https://solidarites-sante.gouv.fr/IMG/pdf/rapport_antibiotiques.pdf
6
https://solidarites-sante.gouv.fr/actualites/presse/communiques-de-presse/article/coup-d-envoi-du-programme-prioritaire-de-recherche-sur-l-antibioresistance-429001
7
https://anr.fr/fr/detail/call/antibioresistance-comprendre-innover-agir-appel-a-projets-2020/